Symbicort Turbuhaler 30/60 Specific Clinical Experience Investigation
ENSURE
1 other identifier
observational
1,500
1 country
47
Brief Summary
The purpose of this study is to confirm the safety profile for long term treatment and maximize doses and the control status on bronchial asthma in daily clinical usage
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Jan 2010
Typical duration for all trials
47 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
January 1, 2010
CompletedFirst Submitted
Initial submission to the registry
October 31, 2010
CompletedFirst Posted
Study publicly available on registry
November 2, 2010
CompletedPrimary Completion
Last participant's last visit for primary outcome
May 1, 2013
CompletedStudy Completion
Last participant's last visit for all outcomes
May 1, 2013
CompletedMay 29, 2013
May 1, 2013
3.3 years
October 31, 2010
May 28, 2013
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Incidence of Adverse Events
Range of one year
Secondary Outcomes (2)
The level of asthma control under long-term use
At the end of 24 weeks
The level of asthma control under long-term use
At the end of one year
Eligibility Criteria
Patients treated with Symbicort for the first time due to bronchial asthma
You may qualify if:
- Patients treated with Symbicort for the first time possibly at the higher dose due to bronchial asthma
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- AstraZenecalead
Study Sites (47)
Research Site
Aichi, Japan, Japan
Research Site
Akita, Japan, Japan
Research Site
Aomori, Japan, Japan
Research Site
Chiba, Japan, Japan
Research Site
Ehime, Japan, Japan
Research Site
Fukui, Japan, Japan
Research Site
Fukuoka, Japan, Japan
Research Site
Fukushima, Japan, Japan
Research Site
Gifu, Japan, Japan
Research Site
Gunma, Japan, Japan
Research Site
Hiroshima, Japan, Japan
Research Site
Hokkaido, Japan, Japan
Research Site
Hyōgo, Japan, Japan
Research Site
Ibaraki, Japan, Japan
Research Site
Ishikawa, Japan, Japan
Research Site
Kagawa, Japan, Japan
Research Site
Kagoshima, Japan, Japan
Research Site
Kanagawa, Japan, Japan
Research Site
Kochi, Japan, Japan
Research Site
Kumamoto, Japan, Japan
Research Site
Kyoto, Japan, Japan
Research Site
Mie, Japan, Japan
Research Site
Miyagi, Japan, Japan
Research Site
Miyazaki, Japan, Japan
Research Site
Nagano, Japan, Japan
Research Site
Nagasaki, Japan, Japan
Research Site
Nara, Japan, Japan
Research Site
Niigata, Japan, Japan
Research Site
Numakunai, Japan, Japan
Research Site
Okayama, Japan, Japan
Research Site
Okinawa, Japan, Japan
Research Site
Osaka, Japan, Japan
Research Site
Ōita, Japan, Japan
Research Site
Saga, Japan, Japan
Research Site
Saitama, Japan, Japan
Research Site
Shiga, Japan, Japan
Research Site
Shimane, Japan, Japan
Research Site
Shizuoka, Japan, Japan
Research Site
Tochigi, Japan, Japan
Research Site
Tokushima, Japan, Japan
Research Site
Tokyo, Japan, Japan
Research Site
Tottori, Japan, Japan
Research Site
Toyama, Japan, Japan
Research Site
Wakayama, Japan, Japan
Research Site
Yamagata, Japan, Japan
Research Site
Yamaguchi, Japan, Japan
Research Site
Yamanashi, Japan, Japan
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- STUDY DIRECTOR
Yoshida Shigeru
AstraZeneca
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
October 31, 2010
First Posted
November 2, 2010
Study Start
January 1, 2010
Primary Completion
May 1, 2013
Study Completion
May 1, 2013
Last Updated
May 29, 2013
Record last verified: 2013-05